Search - tctmd.com

Displaying 1 - 20 of 117

Sort: Relevancy | Date

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

News Conference News ACC 2024

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Michael O'Riordan

April 07, 2024

News Conference News ACC 2024

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

Caitlin E. Cox

April 06, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

L.A. McKeown

April 04, 2024

News Conference News ACC 2024

Heavy Drinking May Contribute to CHD Risk in Young Women

L.A. McKeown

April 02, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

Advertisement

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

What’s Going to Be Hot at ACC 2025?

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI

Oral Device Noninferior to CPAP for Reducing BP in Sleep Apnea: CRESCENT

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Faster CAC Progression After Menopause May Warrant Intensified Therapy

Heavy Drinking May Contribute to CHD Risk in Young Women

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content